MFAM
AKCA

Motley Fool Asset Management’s Akcea Therapeutics Inc AKCA Stock Holding History

Motley Fool Asset Management’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-70,312
Closed -$1.27M – 168
2020
Q3 		$1.27M Buy
70,312
+4,653
+7% +$66K 0.11% 109
2020
Q2 		$900K Buy
65,659
+5,687
+9% +$87.7K 0.09% 112
2020
Q1 		$858K Sell
59,972
-517
-0.9% -$8.49K 0.11% 108
2019
Q4 		$1.02M Sell
60,489
-2,068
-3% -$38.5K 0.11% 103
2019
Q3 		$963K Sell
62,557
-1,034
-2% -$22K 0.11% 105
2019
Q2 		$1.49M Buy
63,591
+1,034
+2% +$25.5K 0.17% 87
2019
Q1 		$1.77M Buy
62,557
+10,340
+20% +$301K 0.2% 86
2018
Q4 		$1.57M Buy
+52,217
New +$1.46M 0.22% 72

Motley Fool Asset Management's AKCA Position: Q4 2020 in Review

Motley Fool Asset Management sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 70,312 shares — an estimated $1.27M sold.

Motley Fool Asset Management first reported a position in AKCA in Q4 2018 and held it in 8 quarters. The position peaked at $1.77M in Q1 2019. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

  • Motley Fool Asset Management reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
  • Motley Fool Asset Management sold 70,312 Akcea Therapeutics Inc shares in Q4 2020, an estimated $1.27M.
  • Motley Fool Asset Management first reported a position in Akcea Therapeutics Inc in Q4 2018 and held it in 8 quarters.
  • Motley Fool Asset Management's Akcea Therapeutics Inc position peaked at $1.77M in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on Motley Fool Asset Management's 13F filing for Q4 2020, filed 12 Feb 2021.